Not yet recruiting
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07852637· Phase 4· Samsung Medical Center· Source
Contact: Hyukjin Park
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
NCT07449754· Phase 2· Hanmi Pharmaceutical Company Limited· Source
Contact: Young Su (Bobby) Noh
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· Phase 3· Kura Oncology, Inc.· Source
Recruiting
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
NCT07062536· Phase 2· Seoul National University Bundang Hospital· Source
Contact: Hyun Jong Kim, MD, PhD
Active, not recruiting
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033· Phase 3· PharmaEssentia· Source
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
NCT06516679· Phase 2· Yonsei University· Source
Contact: Hee Jo Baek
Recruiting
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06645678· Phase 1/2· YOUNGIL KOH· Source
Contact: Youngil Koh, MD, PhD
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Recruiting
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394· Phase 2· Hyoung Jin Kang· Source
Contact: Hee Jo Baek, Professor
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Young-Chul Kim, Site 0458
Recruiting
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
NCT06698887· Bristol-Myers Squibb· Source
Contact: Sung Hoon Jung, Site 0041
Active, not recruiting
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273· Phase 2· Allogene Therapeutics· Source
Contact: Deok-Hwan Yang, MD (principal investigator)
Recruiting
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
NCT05827549· Phase 2· Ho Joon Im· Source
Contact: Hee Jo Baek, Ph.D
Recruiting
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
NCT06099366· Phase 2· Hee Young Ju· Source
Contact: Hee Jo Baek, Professor
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Young-Chul Kim (principal investigator)
Active, not recruiting
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Celgene· Source
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578· Phase 2· Toray Industries, Inc· Source
Contact: Principal Investigator
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT05841472· Phase 2· CrystalGenomics, Inc.· Source
Contact: Injae Oh, M.D.
Active, not recruiting
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
NCT05557591· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
NCT05845489· Phase 4· Seoul National University Hospital· Source
Contact: Ju Han kim, MD,PhD
Enrolling by invitation
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972· Zimmer Biomet· Source
Recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797· Phase 2· Fore Biotherapeutics· Source
Contact: Jessica Rine
Recruiting
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
NCT05534087· Phase 3· Seoul National University Hospital· Source
Contact: Sang Hee Cho, M.D.,Ph.D
Active, not recruiting
A Study of Daratumumab
NCT05438043· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085· Phase 3· Celgene· Source
Contact: Sung Hoon Jung, Site 0085
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171· Phase 2/3· Panbela Therapeutics, Inc.· Source
Contact: Jun Eul Hwang, MD
Recruiting
Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr
NCT05421650· CHA University· Source
Contact: Seok Mo Kim (principal investigator)
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source
Contact: Jae-Sook Ahn, MD
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· Phase 3· Amgen· Source
Active, not recruiting
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811· Phase 2· Nuvation Bio Inc.· Source
Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· Phase 3· HUYABIO International, LLC.· Source
Active, not recruiting
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934· Phase 3· Daiichi Sankyo· Source
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Contact: enGene clinical trials
Active, not recruiting
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source
Active, not recruiting
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
NCT03426904· Phase 3· Kyungpook National University Hospital· Source
Active, not recruiting
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NCT04077099· Phase 1/2· Regeneron Pharmaceuticals· Source
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766· Phase 1/2· Inhibrx Biosciences, Inc· Source
Contact: In-Jae Oh, MD, MS, PhD (principal investigator)
Active, not recruiting
Safety and Efficacy of the ANTHEM™ CR Total Knee System
NCT03885622· Smith & Nephew Pte Ltd· Source
Showing 50 of 52.